WAY-316606 is primarily used in biomedical research as a selective inhibitor of the enzyme CYP2C9, which plays a key role in drug metabolism. It is also studied for its ability to modulate the Wnt signaling pathway by targeting secreted frizzled-related proteins (sFRPs), making it a valuable tool in bone regeneration studies. Researchers use WAY-316606 to enhance osteoblast activity and promote bone formation, particularly in models of osteoporosis and other bone-deficient conditions. Its application in tissue engineering focuses on improving the healing of skeletal tissues by stimulating stem cells to differentiate into bone-forming cells. Due to its specific mechanism, it is often employed in preclinical studies to evaluate potential therapies for bone loss and joint-related diseases.